Literature DB >> 18552360

Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology.

J Emmering1, N C Krak, J J M Van der Hoeven, M D Spreeuwenberg, J W R Twisk, S Meijer, H M Pinedo, O S Hoekstra.   

Abstract

BACKGROUND: Established prognosis-based criteria determine the need for further treatment after primary surgery for breast cancer. Such criteria are lacking after neo-adjuvant chemotherapy. We determine the prognostic value of preoperative [(18)F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography ((18)FDG-PET) after chemotherapy in locally advanced breast cancer (LABC), both as independent indicator and as add-on to postoperative histopathology. PATIENTS AND METHODS: Preoperative PET was carried out in 40 LABC patients. Two expert readers assessed residual (18)FDG uptake in the primary tumor. At histopathological examination of the surgical specimen, chemotherapy response was graded using the Honkoop criteria. Cox proportional hazards analysis was used to determine prognostic relevance of PET and histopathology.
RESULTS: Median follow-up was 60 months (range 15-94), during which 13 patients had recurrent disease, eight of whom died. (18)FDG uptake in the primary tumor was inversely related with disease-free survival (DFS) [hazard ratio (HR) 4.09; 95% confidence interval (CI) 1.26-13.31; P = 0.02] and this was superior to histopathology (HR 2.52; 95% CI 0.77-8.23; P = 0.13). Observer agreement of PET was excellent (intraclass correlation coefficient 0.88). Multivariate Cox regression revealed no added value of histopathology versus PET results.
CONCLUSION: (18)FDG uptake in the primary tumor at PET was inversely associated with DFS and may help to guide adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552360     DOI: 10.1093/annonc/mdn185

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

1.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

2.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.

Authors:  Albert E Cerussi; Vaya W Tanamai; David Hsiang; John Butler; Rita S Mehta; Bruce J Tromberg
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

3.  Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.

Authors:  Albert E Cerussi; Vaya W Tanamai; Rita S Mehta; David Hsiang; John Butler; Bruce J Tromberg
Journal:  Acad Radiol       Date:  2010-06-12       Impact factor: 3.173

4.  Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer.

Authors:  Jahae Kim; Su Woong Yoo; Sae-Ryung Kang; Sang-Geon Cho; Jong-Ryool Oh; Ari Chong; Jung-Joon Min; Hee-Seung Bom; Jung-Han Yoon; Ho-Chun Song
Journal:  Nucl Med Mol Imaging       Date:  2012-08-25

5.  Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.

Authors:  Darren Roblyer; Shigeto Ueda; Albert Cerussi; Wendy Tanamai; Amanda Durkin; Rita Mehta; David Hsiang; John A Butler; Christine McLaren; Wen-Pin Chen; Bruce Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

6.  Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Authors:  Suyun Chen; Nuhad K Ibrahim; Yuanqing Yan; Stephen T Wong; Hui Wang; Franklin C Wong
Journal:  Oncologist       Date:  2017-04-04

7.  Molecular imaging of solid tumors: exploiting the potential.

Authors:  Wim J G Oyen; Winette T A van der Graaf
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

8.  The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.

Authors:  Michal E Schneider-Kolsky; Stewart Hart; Jane Fox; Peter Midolo; John Stuckey; Michael Hofman; Vinod Ganju
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466

9.  (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Selin Carkaci; Christopher T Sherman; Efe Ozkan; Beatriz E Adrada; Wei Wei; Eric M Rohren; Osama R Mawlawi; Naoto T Ueno; Thomas A Buchholz; Wei T Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-23       Impact factor: 9.236

10.  Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

Authors:  Bhumsuk Keam; Seock-Ah Im; Youngil Koh; Sae-Won Han; Do-Youn Oh; Nariya Cho; Jee Hyun Kim; Wonshik Han; Keon Wook Kang; Woo Kyung Moon; Tae-You Kim; In Ae Park; Dong-Young Noh; June-Key Chung; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.